The AI Agent Arms Race: Latest OutSystems AI Study Reveals 93% of Software Executives Plan to Introduce Custom AI Agents Within Their Organizations

Analytics Insight
Jul 21, 2025 12:00
Analytics Insight
1 views
aianalyticsbig-databusiness

Summary

A recent OutSystems study reveals that 93% of software executives plan to implement custom AI agents in their organizations, signaling a rapid acceleration in AI agent adoption. This trend highlights growing confidence in AI's potential to drive business value and intensifies competition in the development of advanced, tailored AI solutions. The findings suggest that AI agents are poised to become a central component of enterprise software strategies.

Related Articles

XRP vs Chainlink: Which Crypto Could Make You a Millionaire?

Analytics InsightJul 22

The article compares XRP and Chainlink, analyzing their potential to generate significant returns for investors. While primarily focused on cryptocurrency investment, it highlights how Chainlink’s AI-driven smart contract capabilities could play a pivotal role in the future of decentralized finance. This suggests that advancements in AI integration with blockchain technology may influence the success and adoption of such digital assets.

Skipped Early Cardano (ADA)? Don’t Miss Ruvi AI’s (RUVI) Audited Token While Still Cheap, Experts Say It’s Next to Rally

Analytics InsightJul 22

The article highlights Ruvi AI's (RUVI) audited token as a promising investment opportunity in the AI sector, drawing comparisons to the early days of Cardano (ADA). Experts suggest that RUVI's low current price and recent audit position it for significant growth, signaling increasing investor interest in AI-driven blockchain projects. This trend underscores the growing convergence of AI and blockchain technologies in the crypto market.

AI-Designed Drugs Can Target 'Undruggable' Proteins in Cancer and Alzheimer's

Hacker News - AIJul 22

AI-driven drug discovery is enabling the design of molecules that can target previously "undruggable" proteins involved in diseases like cancer and Alzheimer's. This breakthrough expands the range of treatable conditions and demonstrates AI's transformative potential in accelerating and broadening pharmaceutical innovation.